Jeremy Szafron: Hey everyone and welcome back to Investors Scene. We had Dr. Rakesh Jetly on the show. It’s an incredible story and I’m excited to introduce the co-founder and the chief science officer of Mydecine Evolved. Rob Roscow now joining us.
Rob Roscow: Thanks Jeremy for having me and I’m excited to talk to you today.
Jeremy Szafron: I’m excited to. The company is doing very well on this side of the operations. We are talking about real compounds. You have so much experience and let’s talk about Mydecine Evolved.
Rob Roscow: It was founded on the exciting potential to develop the current clinical trial data and excitement around psychedelic space and assistance and the betterment of mental health therapy. Also, taking the increasing interest of the general public and to run forward with that. The situation currently is exciting because there is a perfect storm of interest and a desire to answer questions. The medical science is catching up to this public desire and enabling this to move forward quickly. This brewing interest is what got me excited about this space and is a backdrop for the company.
Jeremy Szafron: We were talking to Dr. Rakesh Jetly yesterday and he was talking about the fact that this is a destigmatized arena now. Mental health has never been more at the forefront of what we care about. Let’s talk about these unique medical compounds. It’s an interesting company.
Rob Roscow: What we have is an effective product that shows strong promise. How can we take this product though and make it useful in a medical context? My role is to question “how can we do this?” We can think about “how can we make this more compatible and useful in therapy.” It looks like being able to control dosage, potency of the medication and also to understand when and where to best use it and to also monitor patients and to use it at the most appropriate time.
The exciting thing is that this is expensive work, and because it is novel concepts and applications, it describes a nice patentable roadmap to how we do this. The patents allow us to secure, fund and enable the value of the work in the long run. It’s exciting to work as a scientist right now because we can see the pathway well into the future.
Jeremy Szafron: We have seen it in the Cannabis sector. We can grab a compound, figure out what the cannabinoid is, and put it into other products. I am curious as to what this process looks like here? When you talk about bringing the dose down to something that has huge efficacy in a shorter period of time, what does this scientific place look like for you?
Rob Roscow: The comparison to cannabis is a nice one. I think of the space around medical use as similar to the medical use of cannabis, but 20 years less so. If we think about the analogy, we have a prime compound like THC, but other minor cannabinoids are showing medical interest. This diversity also exists in our sphere. We are looking at diversity and it’s partly that diversity that allows us to continue.
Mydecine Evolved is working with large universities and has great trials going on
Jeremy Szafron: I can talk about this forever. It blows my mind that we can isolate something, put it in a better situation and help people. The company is talking about other companies and you are working with large universities and have great trials going on. Can you talk a bit about those?
Rob Roscow: As a company, we view the usage as a medical avenue. We spent the last year, since founding the company, putting together a large group of clinical trials, directed at the question: “how can we best use this in combination with therapy?” If we look at our PTSD trials, those are set out to ask these questions. Styles of therapy? How often do you use our product in therapy situations?
We are looking at it in a pointed fashion where we can make that repeatable and scalable to the larger PTSD community. We are effectively pointing in that direction. We are also sponsoring pre-clinical stage trials to understand what the lowest therapeutic dosage is and how we can make it more usable in the medical context. Understanding this and other effects necessary is a prime interest and an open question in the field.
Jeremy Szafron: We are at the tip of the iceberg here. We are just getting started. When you look back to when you started, how excited are you?
Rob Roscow: I am incredibly excited. The amount of interest built over the last year, especially from more traditional pharmaceutical camps is exciting. There is so much medical potential and has been underserved. It speaks well for the ability to continue this research. I make the comparison that this is moving 4 to 6 times faster than the cannabis space was in 2015-2017. It’s very pointed and accelerated with a clinical focus. This almost provides more focus to the industry.
Jeremy Szafron: You know that every pharmaceutical company is having these discussions silently in their board room. Thanks for being on the show and looking forward to having you back on.
Rob Roscow: Thanks Jeremy.